Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Soliris Filing Planned In Second-Half Of 2006; "TRIUMPH" Pivotal Aptly Named?

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Alexion plans to submit its biologic Soliris for treatment of paroxysmal nocturnal hemoglobinuria in the U.S. and EU in the second half of 2006

You may also be interested in...



Alexion EXPLOREs priming the PNH market

In advance of a BLA for its paroxysmal nocturnal hemoglobinuria treatment Soliris (eculizumab), Alexion is raising the profile of the orphan blood disorder with a diagnostic study and website. The company says that PNH patients can "go undiagnosed for years." Because PNH "is associated with bone marrow disorders [but] is often misdiagnosed or undetected in these patients," Alexion's EXPLORE study will engage approximately 200 hematologists and 2,000 patients in "the first systemic effort to determine the presence of the PNH blood cell clone" in patients with aplastic anemia, myelodysplastic syndrome and related disorders, the company says. Enrollment will begin this summer. The website - PNHSource.com - "will serve as the first PNH-specific, on-line informational resource," Alexion adds. Soliris Phase III data is expected later this year (1Pharmaceutical Approvals Monthly February 2006, p. 10); the company recently said BLA filing was possible by year-end...

Alexion Eculizumab Will Have "Ultra-Orphan" Price; Antibody Enters Phase III

Alexion plans to price its biologic eculizumab for treatment of paroxysmal nocturnal hemoglobinuria similarly to other high-priced agents for very rare diseases, the firm indicated.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel